Baxter International Inc. (NYSE: BAX ) — This global medical products and services company is a leader in critical therapies for life-threatening conditions. The company’s profit margins are expected to improve from 2010′s 51.4%, and revenues are expected to rise by about 5%, according to S&P. But recent challenges to the health-care reform act, if successful, could have a strong positive impact on Baxter’s earnings, which are currently estimated to be $4.30 in 2011, up from $3.98 in 2010. S&P maintains a “four-star buy” on the stock with a 12-month target of $58. But that target could be achieved much sooner if the recent triple-top is penetrated and the stock moves into the open gap at $52 to $58. Buy this high-quality health-care equipment maker on either a break from the top at $52 or a pullback to the 50-day moving average at $50. If you have questions or comments for Sam Collins, please e-mail him at samailc@cox.net .
Negocioenlinea
tdp2664
gol2664
InvestorPlace
TODAY'S PRICE GOLD,OIL,DOW JONES,NASDAQ,S&P500,YHOO,GOOG,MSFT,CSCO,AAPL,RNWK,DJIA,GSPC,TWX,RUSSELL 3000,DJ WILL 5000